JGL SCIENTIFIC ADVISORY BOARD (JGL SAB) is an independent, international, advisory body of eminent scientists and experts whose areas of interest fall into the company's strategic therapeutic areas - influenza and cold, ophthalmology and dermatology, and operating in Europe and the UK, Russia, Ukraine, Turkey and through its network - in other global markets.
It is composed of ten experts, internationally recognised in their fields of work - pharmacology, preclinical, clinical and regulatory stages of drug development, pharmaceutical product design, drug delivery systems and technologies, and practical regulatory and clinical and industrial experience.
The main goals for the SAB meeting
- Strengthen the scientific profile of the JGL research and development project / product portfolio
- Network and share relevant, science-based knowledge and ideas
- Review, challenge and advise the JGL team on ongoing R&D projects
- Provide scientific explanations and adequacy of performance data and plans
- Work with the JGL team and other SAB members to gather additional ideas for the portfolio and identify new projects with a sound scientific rationale
- Present the area of own expertise through lectures and discussions
- Advise the JGL Board of Directors in special strategic decisions
PROF. DR. SC. HENNING H. BLUME, DR.MED
Prof. dr. sc. Henning H. Blume, MD, is the founder and owner of SocraTeca C&S (Concepts and Strategies in Clinical Drug Development) and Professor of Pharmacy at the University of Frankfurt. He is a globally recognized expert in the broad field of biopharmaceuticals who supports numerous clients with his highly sophisticated consulting activities. Born in 1947, he received his doctorate from the University of Frankfurt in 1973, and completed his postdoctoral research in 1982 as an assistant professor at the Faculty of Pharmacy, University of Frankfurt. His areas of research include biopharmaceutical and pharmacokinetic research, with special emphasis on the characterization of drug bioavailability and bioequivalence. He has published more than 230 scientific papers and is a member of numerous international scientific institutions in the field of biopharmaceuticals and clinical pharmacology. The internationally renowned Semmelweis University of Education and Research awarded him an honorary doctorate for his outstanding contribution to the advancement of science.
PROF. DR. SC. VASIL IVANOVIČ POPOVIČ, DR. MED.
PROF. DR. SC. STIPAN JONJIĆ
Prof. dr. sc. Stipan Jonjić was born in 1953 and he is a professor and head of the Department of Histology and Embryology, and the head of the Center for Proteomics at the Medical Faculty of the University of Rijeka. His research interests include immunology, viral pathogenesis, vaccines and immunotherapy. In 2012, Jonjić became the first Croatian scientist to be admitted to Leopoldin, the German National Academy of Sciences, and in 2015 he was admitted to the European Academy of Microbiology. In 2006, he founded the Center for Proteomics, which has become one of the most recognizable scientific institutions in Croatia. He is the first Croatian scientist to receive a project in 2012 from the European Research Council (ERC), a scientific research body that funds projects solely on the basis of excellence. He has led projects at the U.S. National Institutes of Health and the Viral Immunology and Vaccine Science Center. The work of prof. Jonjic resulted in a number of important discoveries in the field of viral immunology and vaccinology. He is the author of more than 250 scientific papers, many of which have been published in the most prestigious scientific journals, which makes him one of the most successful Croatian scientists. He has given more than 200 lectures at international scientific conferences and institutions around the world, and collaborates with a large number of world scientists in the field of viral immunology.
PROF. DR. SC. MARINA A. MOKRONOSOVA, DR. MED.
PROF. DR. SC. ÖZGEN ÖZER, DR. MED.
DR. SC. JAG AHLUWALIA, DR. MED.
Dr. sc. Jag Ahluwalia, MD is an experienced leader in the field of regulatory affairs and quality. In her rich professional career, leading positions in Ranbaxy (India), Pliva (Croatia), Xellia Pharmi (Denmark) and Kinedexe UK (own company) stand out. Born in 1962 in Uganda, she holds a PhD in toxicology from the University of Surrey and has more than 35 years of experience in the pharmaceutical industry, from regulatory affairs, quality and product development, to business development. In 2014 she started three pharmaceutical companies in the UK, and her expertise lies in the successful launch of molecules that have been developed and registered using a virtual environment in a cost-effective way. In the areas of industrial pharmaceutical practice and registration, she operates in the EU, the UK, the US, Canada, Asia, Australia and Latin America. Under her leadership, a number of projects have been successfully registered and launched, including FTF products in the United States. Thanks to her significant international experience, Jag Ahluwalia supports numerous projects of registration / entry of medicines into global markets.
PROF. DR. SC. VLADIMIR TRKULJA, DR. MED.
PRIM. DR.SC. SONJA JANDROKOVIĆ, DR. MED.
Prim.dr.sc. Sonja Jandroković, MD was born in 1969 in Beijing. She is the head of the Day Hospital and One-Day Surgery at the Clinic for Eye Diseases, University Hospital Center Zagreb. After graduating from the Medical Faculty of the University of Zagreb in 1993, she specialized in ophthalmology, and chose glaucomatology as her specialization. She received her PhD in 2017 in the study of "Biomedicine and Health" at the Faculty of Medicine, University of Zagreb. She actively participates in numerous scientific and professional conferences in the country and abroad, as well as in first category courses and evaluated scientific lectures. She is the author or co-author of 16 scientific and professional papers and several publications in journals. From the academic year 2011/2012 she participates in the teaching of the Faculty of Medicine, University of Zagreb, and has also lectured at the university postgraduate specialist studies "Ophthalmology" and "Ophthalmology and Optometry". She is the co-leader of the "Glaucoma" course.
DR. SC. ANDREAS BILSTEIN
Born in 1974, Andreas Bilstein is an experienced scientist, consultant and CEO of Urastech with many years of experience in the pharmaceutical industry. His areas of interest include medical product development, business development, clinical trial management, biotechnology, and regulatory requirements and management. His professional career (2007-2019) is primarily related to the global company Bitop AG (Dortmund, Germany) where he was a member of the Executive Board and CEO of scientific and technological operations, responsible for new product development, research and development, quality management , regulatory affairs and production. Dr. Bilstein received his PhD in 2005 from the Institute of Biochemistry, Faculty of Medicine, University of Cologne.prof.
PROF. DR. SC. JASMINA LOVRIĆ, MAG. PHARM
Prof. dr. sc. Jasmina Lovrić was born in 1977. She completed her studies in pharmacy at the Faculty of Pharmacy and Biochemistry, University of Zagreb (FBF) in 2001, and her doctorate in pharmaceutical sciences in 2006. During her doctoral studies, she spent three years at McGill University (Montreal, Canada). For her doctoral dissertation in 2006, she was awarded the prize of the Society of University Teachers and Other Scientists. As a Research Fellow in 2006, she joined the FBF Department of Pharmaceutical Technology. Three years later, she acquired the scientific-teaching title of assistant professor, and in 2015 the scientific-teaching title of associate professor. Scientific activity of dr. sc. Lovrić resulted in the publication of 38 highly scientific papers, two chapters in scientific books and 60 conference papers. She is the supervisor of two doctoral theses, 34 diploma theses and five specialist theses. Her special areas of expertise are technologies, characterization and delivery systems for products in ophthalmology. She was the Vice-Dean for Science and Research at the Faculty of Pharmacy and Biochemistry for two terms, and since October 2020 she has been the Dean of the Faculty of Pharmacy and Biochemistry.